Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Study Type: Interventional
Age/Gender Requirements: 18 years (male/female)
Sponsor: Morphotek
Purpose: Researchers are looking into the safety, tolerability, and efficacy “of farletuzumab in subjects with resectable, non-functioning pituitary macroadenomas as measured by objective response in the tumor size” because “previous clinical work suggests there may be a role for a folate receptor in the treatment” of these tumors.
http://hcp.lv/e6Rtrr